Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 11/20 | 0.56 |
| ▸ | APAF1 | O14727 | 6/20 | 0.56 |
| ▸ | CASP3 | P42574 | 5/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.56 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.56 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | THRB | P10828 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | UBE2I | P63279 | 2/20 | 0.56 |
| ▸ | GALK1 | P51570 | 1/20 | 0.56 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.56 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784203 | 1.00 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL6648718 | 0.81 | MEN1 (0.49) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL6646947 | 0.78 | PARP1 (0.52) | KDM4EALDH1A1LMNASMN1; SMN2PARP1 | |
| SCHEMBL6448568 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL824574 | 0.75 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1687342 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL5311576 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1818129 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL1719778 | 0.75 | LOXL2 (0.61) | KDM4EGAALOXL2CDC25BAPAF1 | |
| SCHEMBL29844316 | 0.75 | LOXL2 (0.61) | KDM4EGAALOXL2CDC25BAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3044221-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011159926-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156626-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010127307-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-11-04 | — | — | WO | disclosed |
| US-7049473-B2 | Hydroformylation | BASF AKTIENGESELLSCHAFT (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1486481-A2 | Hydroformylation process | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-15 | — | — | EP | disclosed |
| US-20040199024-A1 | Using catalyst containing transition metal and ligand; reacting carbon monoxide and hydrogen | BASF AKTIENGESELLSCHAFT (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-3961062-A | Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | KDM4E 2001/4885GAA 1316/4885LOXL2 2790/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | KDM4E 2009/4885GAA 1492/4885LOXL2 181/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | KDM4E 2586/4885GAA 379/4885LOXL2 4680/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | KDM4E 2009/4885GAA 1492/4885LOXL2 181/4885 |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | KDM4E 1176/4885GAA 2698/4885LOXL2 2061/4885 |
| US-20040199024-A1 | Using catalyst containing transition metal and ligand; reacting carbon monoxide and hydrogen | NUDT1, PPIP5K2, HAO2 | KDM4E 3889/4885GAA 4218/4885LOXL2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.